EUVIMEDEUVIMED entdecken
Korrektur

Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar

Seminars in Liver Disease · 01.02.2024 · 44 (01) · e1-e3

DOI: 10.1055/s-0044-1787737 ↗

Kurz gefasst

Korrektur in der Zeitschrift Seminars in Liver Disease, erschienen am 01.02.2024. Verfasst von Hao Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Correction to: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future Semin Liver Dis 2024; 44(01): 079-098 DOI: 10.1055/a-2242-7543 It has been brought to the publisher's attention that the following errors were made in the above article published in Seminars in Liver Disease, volume 44, Number 1 (DOI: 10.1055/a-2242-7543 ): [ Figure 3 ] and [ Table 3 ], washout period data derived from Nordness et al. is noted to be 4 months instead of the correct 8 days. On page 87 paragraph 5, sentence 10, the original sentence reads “In fact, the two fatalities occurred after the longest washout periods, 89,95 whereas three patients with washout periods of a week or less experienced no rejection. 79 ” The corrected line is: “In fact, one of the two fatalities occurred after the longest washout periods, 89,95 whereas three patients with washout periods of a week or less experienced no rejection. 79 ” All the above errors have been corrected in the HTML version of the article. The corrected figure and table are depicted below. The error does not change the conclusion of the article. Fig. 3 The washout period of all reported patients who had immune checkpoint inhibitors as bridging or downstaging therapy before liver transplant for hepatocellular carcinoma, divided into whether liver allograft rejection happened. Red: patients who died from rejection. Green: data from Chouik et al, 98 Solino et al, 88 and Sogbe et al, 85 where the exact washout period was not reported. Table 3 All reported patients so far who had immune checkpoint inhibitors as bridging or downstaging therapy before liver transplant for hepatocellular carcinoma Author and year Age Sex (M/F) Regimen Length of treatment Washout period Rejection Survival Follow-up length Chouik 2023 98 57 M Atezolizumab/Bevacizumab 18 cycles Not reported, around 2 months No Yes 10 months Rudolph 2023 91 47 F Nivolumab 7 doses 55 days No Yes 48 months Schmiderer 2023 90 63 M Atezolizumab/Bevacizumab 6 months 6 weeks No Yes 12 months Tow 2022 99 na M Nivolumab 8 weeks 6 weeks Yes Yes 22 days Aby 2022 96 64 M Nivolumab 23 cycles 16 days Yes Yes 16 months Qiao 2021 82 53 (average) M/F 7/0 patients Pembrolizumab 1–5 cycles 1.3 months 1/7 Yes 15 days Schnickel 2022 81 Dave 2022 94 Dehghan 2021[ c ] 83 61 F Nivolumab 18 months 5 weeks Yes[ c ] Yes 38 months 65 M Nivolumab 8 months 10 days Yes Yes 13 months 71 M Nivolumab 8 months 3 months No Yes 16 months 65 F Nivolumab 12 months 4 months No Yes 11 months 68 M Nivolumab 12 months 6 months No No[ a ] 2 months Abdelrahim 2022 97 66 M Atezolizumab/Bevacizumab 6 cycles 8 weeks No Yes 1 year Kang 2022 93 14 M Pembrolizumab 9 weeks 138 days No Yes 4 years Kang 2022 92 23 F Nivolumab 6 months 6 months No Yes 6 months Chen 2021 95 39 M Toripalimab 10 cycles 93 days Yes No[ b ] 71 hours Nordness 2020 89 65 M Nivolumab 22 months 8 days Yes No[ b ] 10 days Chen 2021 80 64 M Nivolumab 1 cycle 7 days No Yes 26 months 47 F Nivolumab 1 cycle 122 days No Yes 9 months 50 M Nivolumab 1 cycle 62 days No Yes 8 months 38 M Nivolumab 6 cycles 59 days No Yes 13 months 67 M Nivolumab 6 cycles 67 days No Yes 7 months Solino 2023 88 68 M Atezolizumab/Bevacizumab 6 cycles Not reported, around 2 months No Yes 14 months Lizaola-Mayo 2021 87 63 M Ipilimumab and Nivolumab 6 months 9 weeks No Yes 6 months Schwacha-Eipper 2020 86 62 M Nivolumab 34 cycles 15 weeks No Yes 12 months Sogbe 2021 85 61 M Durvalumab 15 months Not reported, > 3 months No Yes 24 months Tabrizian 2021 79 69 M Nivolumab 21 cycles 18 days No Yes 23 months 56 F Nivolumab 8 cycles 22 days No Yes 22 months 58 M Nivolumab 32 cycles 1 day No Yes 22 months 63 M Nivolumab 4 cycles 2 days No Yes 21 months 30 M Nivolumab 25 cycles 22 days Yes Yes 16 months 63 M Nivolumab 4 cycles 13 days No Yes 14 months 66 M Nivolumab 9 cycles 253 days No Yes 14 months 55 F Nivolumab 12 cycles 7 days No Yes 8 months 53 F Nivolumab 2 cycles 30 days No Yes 8 months Peterson 2021 84 68 M Nivolumab 6 months 10 months No Yes 7 months a Death due to cardiac event with functioning liver allograft. b Death due to rejection and graft failure. c Salvaged with retransplantation. Publication History Article published online: 05 June 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Autor:innen und Institutionen

  • Department of Surgery, Starzl Transplant Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Division of Transplant Surgery, Department of Surgery, Mayo Clinic Arizona, Phoenix, Arizona.
  • Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Liu, H., Sethi, V., Li, X., Xiao, Y., & Humar, A. (2024). Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in Liver Disease, 44(01), e1-e3. https://doi.org/10.1055/s-0044-1787737

Vancouver

Liu H, Sethi V, Li X, Xiao Y, Humar A. Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in Liver Disease. 2024;44(01):e1-e3. doi:10.1055/s-0044-1787737

BibTeX
@article{Liu2024,
  author = {Liu, Hao and Sethi, Vrishketan and Li, Xingjie and Xiao, Yao and Humar, Abhinav},
  title = {Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future},
  journal = {Seminars in Liver Disease},
  year = {2024},
  volume = {44},
  number = {01},
  pages = {e1--e3},
  doi = {10.1055/s-0044-1787737}
}
Kostenlos starten →